Zandelisib Displays Exemplary Efficacy in Relapsed/Refractory Follicular Lymphoma

Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.

Related Keywords

Poland ,Wojciech Jurczak ,Astrazeneca ,